Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$47.13 USD

47.13
2,915,615

-0.30 (-0.63%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $47.15 +0.02 (0.04%) 6:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (85 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Emergent (EBS) Earnings Miss in Q4, Revenues Beat Estimates

by Zacks Equity Research

Emergent's (EBS) earnings lag estimates in Q4 while revenues surpass the mark.

Kinjel Shah headshot

Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval

by Kinjel Shah

AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.

Zacks Equity Research

What's in the Cards for Amarin (AMRN) This Earnings Season?

by Zacks Equity Research

Amarin's (AMRN) fourth-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.

Zacks Equity Research

Sanofi, J&J Join Forces With BARDA for Coronavirus Vaccine

by Zacks Equity Research

Sanofi (SNY) and J&J (JNJ) sign deals with BARDA, part of U.S. Department of Health and Human Services, for accelerated development of a vaccine for the newly found coronavirus.

Sheraz Mian headshot

Top Research Reports for Facebook, Netflix & NextEra Energy

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Netflix (NFLX) and NextEra Energy (NEE).

Zacks Equity Research

Regeneron Reports Positive Eylea Data From Late-Stage Study

by Zacks Equity Research

Regeneron (REGN) announces positive two-year results from the phase III PANORAMA study on lead ophthalmology drug, Eylea.

Kinjel Shah headshot

Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split

by Kinjel Shah

Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.

Zacks Equity Research

Alnylam's (ALNY) Q4 Earnings Miss Estimates, Sales Beat

by Zacks Equity Research

Alnylam (ALNY) posts a wider-than-expected loss, while revenues beat estimates marginally in the fourth quarter of 2019.

Zacks Equity Research

Sanofi (SNY) Q4 Earnings Top, Sales Miss, Dupixent Strong

by Zacks Equity Research

Sanofi (SNY) reports mixed fourth-quarter results with strong Specialty Care and Vaccines sales but soft Consumer Healthcare sales

Zacks Equity Research

Regeneron's (REGN) Q4 Earnings & Sales Surpass Estimates

by Zacks Equity Research

Regeneron (REGN) beats on Q4 earnings and sales on solid performance of ophthalmology drug, Eylea, and asthma drug, Dupixent.

Zacks Equity Research

Novo Nordisk (NVO) Q4 Earnings Match Estimates, Revenues Beat

by Zacks Equity Research

Novo Nordisk (NVO) posts in-line earnings, while revenues beat estimates in the fourth quarter of 2019.

Zacks Equity Research

Why Earnings Season Could Be Great for Sanofi (SNY)

by Zacks Equity Research

Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off

by Zacks Equity Research

Merck (MRK) beats estimates for earnings but misses the same for sales in fourth-quarter 2019. The company plans to spin off Women Health drugs/biosimilars into new company. Shares down.

Zacks Equity Research

Merck's Recarbrio Gets FDA Priority Review for New Indication

by Zacks Equity Research

The FDA accepts Merck's (MRK) sNDA for antibacterial injection Recarbrio and grants priority review.

Zacks Equity Research

Will Eylea & Dupixent Drive Regeneron's (REGN) Q4 Earnings?

by Zacks Equity Research

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports fourth-quarter 2019 results.

Zacks Equity Research

Lilly's NDA for Selpercatinib Gets FDA's Priority Review

by Zacks Equity Research

Lilly's (LLY) NDA for oral RET inhibitor selpercatinib gains the FDA priority review status for RET-altered lung and thyroid cancers.

Zacks Equity Research

Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data

by Zacks Equity Research

It has been a busy week for the biotech sector with pipeline and regulatory updates from quite a few players.

Zacks Equity Research

Are Investors Undervaluing Sanofi (SNY) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

SNY vs. NVO: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

SNY vs. NVO: Which Stock Is the Better Value Option?

Zacks Equity Research

Regeneron & Sanofi's sBLA for Dupixent Accepted by the FDA

by Zacks Equity Research

The FDA accepts Regeneron (REGN) and Sanofi's sBLA for Dupixent for Priority Review.

Zacks Equity Research

Lilly's Olumiant Meets Primary Goal in Dermatitis Study

by Zacks Equity Research

Eli Lilly (LLY) and partner Incyte's Olumiant meets primary endpoint in atopic dermatitis in a late-stage study.

Zacks Equity Research

Dr. Reddy's (RDY) Q3 Earnings and Revenues Increase Y/Y

by Zacks Equity Research

Dr. Reddy's (RDY) earnings (excluding impairment charge) increase year over year in the third quarter of fiscal 2020.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Merck, Broadcom, Sanofi, Equinix and American Electric Power

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Merck, Broadcom, Sanofi, Equinix and American Electric Power

Sheraz Mian headshot

Top Stock Analyst Reports for Merck, Broadcom & Sanofi

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Broadcom (AVGO) and Sanofi (SNY).

Zacks Equity Research

Should Value Investors Pick Sanofi (SNY) Stock Right Now?

by Zacks Equity Research

Is Sanofi (SNY) a great pick from the value investor's perspective right now? Read on to know more.